New hope for uveitis: Anti-Inflammatory drug tested in chinese patients
NCT ID NCT07663331
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the drug adalimumab (Tebiovio®) in 30 adults with non-infectious uveitis, an inflammatory eye disease. The goal is to see if the drug can control inflammation and prevent treatment failure. Participants will receive injections and be monitored for up to 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adalimumab (a drug that blocks inflammation)
What this could lead to
If successful, this could provide a new treatment option for adults with non-infectious uveitis, helping control inflammation and prevent vision loss.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The drug may not work for all patients and can have side effects like increased infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-INFECTIOUS INTERMEDIATE UVEITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••